Publisher
Springer Science and Business Media LLC
Reference152 articles.
1. Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255–1263 (2022).
2. Strebhardt, K. & Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473–480 (2008).
3. Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490–1496 (2001).
4. Rowe, J. M. & Lowenberg, B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 121, 4838–4841 (2013).
5. ClinicalTrials.gov. Search terms ‘cancer’, ‘antibody drug conjugate’ with phase 1–3 trials of ‘not yet recruiting’, ‘recruiting’, ‘enrolling by invitation’ and ‘active, not recruiting’ status (US National Library of Medicine, accessed 13 March 2022).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献